Docteur Elise DESCAMPS

Bibliographie

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

• 📕

  Le phénotype et la sévérité de la neuropathie des petites fibres dans le syndrome de Sjögren primitif sont-ils différents des autres causes de neuropathie des petites fibres

  2019 · 164 p.

Source : Google Books — filtre catégories médicales/santé/sciences.

Lieu de consultation

• HOPITAL SAINT CAMILLE

  2 Rue DES PERES CAMILLIENS, 94366 Bry-sur-Marne

  ☎ 0149831010Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy

  Rheumatology (Oxford, England) · 2020

  📚 30 citations🎯 RCR 1.37🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Objectives The frequency and consequences of anti-drug antibodies to rituximab (RTX-ADA) are not well known in RA and even less in other systemic auto-immune diseases (sAID). We aimed to evaluate the frequency, consequences and predictive factors of RTX-ADA in RA and sAID. Methods All patients presenting with RA or other sAID treated with RTX from 2012 to 2017 in our tertiary reference centre for sAID were retrospectively studied. Patients who were tested for RTX-ADA were identified. Results One hundred and ninety-nine patients were treated with RTX (RA: 124, other sAID: 75). Among 62/199 (31.1%) tested for RTX-ADA, 14 were positive: 3/35 RA (8.6%) and 11/27 (40.7%) other sAID, (P = 0.0047). Among the whole RTX-treated populations, the frequency of RTX-ADA was 2.4% and 14.7% (P = 0.0026) in RA and sAID, respectively. Most of the immunized patients had infusion reactions to second or subsequent RTX cycles (11/14) and loss of efficacy (2/14). Predictive factors of immunization were sAID vs RA (78.6% vs 21.4%, P = 0.026, adjusted odds ratio (OR) = 5.35[1.43—54.75]) and African ethnicity (57.1% vs 4.2%, P < 0.001, adjusted OR = 9.25 [5.08—302.12]). Associated immunosuppressive therapy did not protect against immunization. Three patients with pSS immunized against RTX were treated with ofatumumab with complete remission of their disease. Conclusion Immunization against RTX is more frequent in other sAID than in RA. Testing for RTX-ADA must be performed in patients with infusion reactions or loss of efficacy especially if they are of African origin. Immunized patients might be treated efficiently and safely with ofatumumab. This alternative should be further evaluated for sAID.

• 2

  Improving accuracy of self-reported diagnoses of rheumatoid arthritis in the French prospective E3N-EPIC cohort: a validation study

  BMJ open · 2019

  📚 20 citations🎯 RCR 1.28🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ObjectivesThe French E3N-EPIC (Etude Epidémiologique auprès des femmes de la Mutuelle générale de l’Education Nationale-European Prospective Investigation into Cancer and Nutrition) cohort enrolled 98 995 women aged 40 to 65 years at inclusion since 1990 to study the main risk factors for cancer and severe chronic conditions in women. They were prospectively followed with biennially self-administered questionnaires collecting self-reported medical, environmental and lifestyle data. Our objective was to assess the accuracy of self-reported diagnoses of rheumatoid arthritis (RA) and to devise algorithms to improve the ascertainment of RA cases in our cohort.DesignA validation study.ParticipantsWomen who self-reported an inflammatory rheumatic disease (IRD) were asked to provide access to their medical record, and to answer an IRD questionnaire. Medical records were independently reviewed.Primary and secondary outcome measuresPositive predictive values (PPV) of self-reported RA alone, then coupled with the IRD questionnaire, and with a medication reimbursement database were assessed. These algorithms were then applied to the whole cohort to ascertain RA cases.ResultsOf the 98 995 participants, 2692 self-reported RA. Medical records were available for a sample of 399 participants, including 305 who self-reported RA. Self-reported RA was accurate only for 42% participants. Combining self-reported diagnoses to answers to a specific IRD questionnaire or to the medication reimbursement database improved the PPV (75.6% and 90.1%, respectively). Using the devised algorithms, we could identify 964 RA cases in our cohort.ConclusionAccuracy of self-reported RA is poor but adding answers to a specific questionnaire or data from a medication reimbursement database performed satisfactorily to identify RA cases in our cohort. It will subsequently allow investigating many potential risk factors of RA in women.

• 3

  Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies

  Muscle & nerve · 2020

  📚 18 citations🎯 RCR 1.69

  Lire l'abstract Crossref ↓

  AbstractIntroductionWe compared histological and clinical profiles of primary Sjögren syndrome (pSS) small fiber neuropathy (SFN; pSS‐SFN) with idiopathic SFN (i‐SFN) and hereditary transthyretin amyloidosis SFN (hATTR‐SFN) and described the evolution of pSS‐SFN.MethodsAll patients with pSS‐SFN, i‐SFN, and hATTR‐SFN confirmed by reduced intraepidermal nerve fiber density on skin biopsy were retrospectively included, and their characteristics were compared. To analyze prognosis of pSS‐SFN, patients prospectively underwent a second evaluation.ResultsFifteen pSS‐SFN, 17 hATTR‐SFN, and 11 i‐SFN were included. Time to diagnosis SFN was longer in pSS‐SFN and i‐SFN than in hATTR‐SFN. Painful and non–length‐dependent patterns were more frequent in pSS‐SFN than in hATTR‐SFN. Twelve (80%) patients with pSS‐SFN had a non–length‐dependent pattern. Ten patients with pSS were reassessed after 3.1 years (1.7–4.7); none developed large fiber neuropathy linked to pSS.DiscussionPrimary Sjögren syndrome SFN is characterized by a more frequent non–length‐dependent pattern compared with i‐SFN and hATTR‐SFN. Primary Sjögren syndrome SFN did not evolve through large fiber neuropathy.

Publications scientifiques (10) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche